Alcon’s Clareon monofocal IOL has gained CE mark approval in the European Union, parent Novartis announced July 18.
Novartis has described Clareon as Alcon’s next-generation polymer material that maintains the benefits of Alcon’s AcrySof platform, including refractive and rotational stability, unfolding characteristics, improved visual outcomes, and a reduction in glistenings and surface haze.
In February, Novartis said it hoped to get US approval of the Clareon by 2019. The company also was targeting 2019 for US approval of its PanOptix trifocal and trifocal toric lenses.